Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rise Of The Biosimilar Formulary: CVS Excludes Lantus, Neupogen For 2017

Executive Summary

Zarxio and Basaglar will be the beneficiaries of the cost-cutting move, although how much it will help the follow-on products remains unclear.


Related Content

A Look At Payers' Early Game Plans For Driving Biosimilar Use
Biosimilar Prescribing Decisions May Depend Upon Disease State
How Risky Is Pfizer’s Launch Of Its Remicade Biosimilar?
UnitedHealthcare Prefers Basaglar Biosimilar At Lantus' Expense
Express Scripts Diabetes Program Caps Drug Costs, Targets Adherence
CVS Expands Formulary Exclusions In 2017, Express Scripts’ Tally Unchanged
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Biosimilar Launch Notification Delay Remains In The US, Might Not Matter For Newer Products
FDA Makes It Official With Basaglar Approval For Diabetes
Zarxio 15% Price Discount To Neupogen In US Tracks European Strategy


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts